Primary Biliary Cirrhosis Drugs Market market is expected to grow at a CAGR of 9.1% during the forecasted period | Evolve Business Intelligence

As per the study initiated by Evolve Business Intelligence, the global Primary Biliary Cirrhosis Drugs Market size accounted for USD 800.1 Million in 2023, growing at a CAGR of 9.1% from 2023 to 2033. Primary biliary cholangitis (PBC) is a chronic liver disease characterized by the inflammation and destruction of the bile ducts within the liver. However, it's important to note that the field of medicine is dynamic, and new information and developments may have occurred since then. The primary goal of drug therapy for PBC is to slow the progression of the disease and manage symptoms. Ursodeoxycholic acid (UDCA) is the primary drug used to treat PBC. UDCA helps to improve liver function and may slow down the progression of the disease. It is considered the first-line treatment for PBC.

Request/Download PDF Sample: https://report.evolvebi.com/index.php/sample/request?referer=OpenPR&reportCode=021545

As the awareness and diagnosis of PBC increase, the demand for effective treatments is likely to rise. Advances in the understanding of the pathophysiology of PBC and ongoing research and development efforts for new and improved therapies can drive the market. Approvals from regulatory agencies for new drugs or expanded indications for existing drugs can significantly impact the market. Since PBC is more common in middle-aged individuals and women, the global aging population may contribute to an increased prevalence of PBC, driving the market for related drugs.

Key Players
Some of the major Primary Biliary Cirrhosis Drugs Market players holding high market shares include Intercept Pharmaceuticals, Inc., Lupin, Zydus Lifesciences Limited, AMAGEN INDIA LIFE SCIENCES, ABC Farmaceutici S.p.a. These players use partnership and collaboration as a key strategy to gain significant market share to compete with market leaders. Some of the other major market players include Ipsen Pharma, GENFIT, Leeford Healthcare Limited, Sun Pharmaceutical Industries Ltd, and Alkem Laboratories Ltd.
For More Information:
https://report.evolvebi.com/index.php/sample/request?referer=OpenPR&reportCode=021545

Segmental Analysis
Based on drug type, the Primary Biliary Cirrhosis Drugs market is segmented into Primary Drugs and secondary Drugs. The primary drugs segment held the largest share in the Primary Biliary Cirrhosis Drugs market. This is because primary drugs are the first-line treatment for primary biliary cirrhosis (PBC), a chronic autoimmune liver disease that affects bile ducts. Primary drugs for PBC include ursodeoxycholic acid (UDCA) and obeticholic acid (OCA). UDCA is a bile acid that is naturally produced in the body, while OCA is a synthetic bile acid. Both UDCA and OCA work by reducing inflammation and slowing the progression of liver damage.

Based on the distribution channel, the Primary Biliary Cirrhosis Drugs market is Hospital Pharmacies, Drugs Stores, and Retail Pharmacies, Online Pharmacies. The hospital pharmacies segment held the largest share in the Primary Biliary Cirrhosis Drugs market. This is because hospital pharmacies are the primary source of PBC drugs for patients who are hospitalized or who require close monitoring. Hospital pharmacies also have access to a wider range of PBC drugs than other distribution channels.
Key Region/ Countries Covered

• North America (US, Canada, Mexico)
• Europe (Germany, U.K., France, Italy, Spain, Russia, Nordic Countries, BeNeLux, Rest of Europe)
• Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Rest of Asia Pacific)
• Middle East and Africa (Saudi Arabia, UAE, Egypt, South Africa, Rest of MEA)
• Latin America (Mexico, Brazil, Argentina, Rest of Latin America)

Address
Evolve Business Intelligence
C-218, 2nd floor, M-Cube
Gujarat 396191
India
Email: sales@evolvebi.com
Website: https://evolvebi.com/

About EvolveBI
Evolve Business Intelligence is a market research, business intelligence, and advisory firm providing innovative solutions to challenging pain points of a business. Our market research reports include data useful to micro, small, medium, and large-scale enterprises. We provide solutions ranging from mere data collection to business advisory.
Evolve Business Intelligence is built on account of technology advancement providing highly accurate data through our in-house AI-modelled data analysis and forecast tool - EvolveBI. This tool tracks real-time data including, quarter performance, annual performance, and recent developments from Fortune's global 2000 companies.

This release was published on openPR.